Innovative liposomes improve thrombolysis in thrombotic environments, indicating potential for safer treatments.
Thrombolytic therapy, exemplified by tissue plasminogen activator, is often constrained by a short half-life, non-specific action, and bleeding risks. To address these limitations, we developed tLipo@UA, a fibrin-targeted and pH-responsive...
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: